Cerliponase Alfa (Brineura) For Cln2 Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Cerliponase alfa (commercially marketed as Brineura) is an FDA-approved enzyme replacement therapy (ERT) specifically indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as late infantile neuronal ceroid lipofuscinosis (LINCL) or Batten disease[1][2]. CLN2 disease is a rare autosomal recessive lysosomal storage disorder caused by mutations in the TPP1 gene (also called CLN2), which encodes the lysosomal enzyme tripeptidyl peptidase 1 (TPP1). The deficiency of TPP1 leads to accumulation of lysosomal storage material (ceroid lipofuscin) in neurons and other cell types, resulting in progressive neurodegeneration, seizures, motor decline, and premature death in affected children[3].
Cerliponase alfa represents a groundbreaking achievement in neurodegenerative disease therapy as the first FDA-approved treatment specifically targeting the underlying enzyme deficiency in any form of neuronal ceroid lipofuscinosis[4]. The development of this therapy required overcoming the significant challenge of delivering a large enzyme molecule across the blood-brain barrier, which was accomplished through direct intracerebroventricular (ICV) administration[5].
Cerliponase alfa is a recombinant human enzyme (rhTPP1) that replaces the deficient endogenous lysosomal enzyme in patients with CLN2 disease[6]. The molecular mechanism involves several key aspects:
Cerliponase alfa is FDA-approved for the treatment of CLN2 disease, a rapidly progressive neurodegenerative disorder typically manifesting between ages 2-4 years[13]:
The approval was based on a pivotal clinical trial program including:
The success of cerliponase alfa has stimulated research into enzyme replacement approaches for other lysosomal storage disorders affecting the central nervous system[20]:
Cerliponase alfa requires specialized administration procedures and infrastructure[24]:
The safety profile of cerliponase alfa has been characterized in clinical trials and post-marketing experience[35]:
| System | Adverse Event | Frequency |
|---|---|---|
| Nervous system | Headache | 53% |
| Nervous system | Seizure | 35% |
| Infections | Device-related infection | 28% |
| General | Pyrexia | 23% |
| Immune system | Hypersensitivity | 18% |
| CSF findings | CSF pleocytosis | 15% |
The study of Cerliponase Alfa (Brineura) For Cln2 Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Schulz A, et al. Cerliponase alfa for the treatment of late-infantile neuronal ceroid lipofuscinosis. 2018. ↩︎
FDA. Brineura (cerliponase alfa) injection, for intracerebroventricular use. 2017. Available at:. 2017. ↩︎
Mole SE, et al. Clinical spectrum of the neuronal ceroid lipofuscinoses: insights from 100 cases. 2021. ↩︎
Scarpa M, et al. Enzyme replacement therapy for lysosomal storage disorders: a developing therapeutic approach. 2017. ↩︎
Fecci P, et al. Intracerebroventricular delivery of therapeutic proteins: clinical utility and challenges. 2020. ↩︎
Johnson TB, et al. TPP1 enzyme replacement therapy improves neurological outcomes in a murine model of CLN2 disease. 2019. ↩︎
Vuillemenot BR, et al. Intracerebroventricular delivery of recombinant human TPP1 (cerliponase alfa) in mouse models of CLN2 disease. 2015. ↩︎
Kohan R, et al. Ceroid lipofuscinosis: the ultrasonic pattern of the disease. 2013. ↩︎
Urayama A, et al. Mannose 6 receptor-mediated cellular uptake of cerliponase alfa. 2018. ↩︎
Gieselmann V. Delivery of therapeutic proteins to the CNS. 2018. ↩︎
Markham A. Cerliponase alfa: first global approval. 2017. ↩︎
Schulz A, et al. Dose-response effect of cerliponase alfa in CLN2 disease. 2019. ↩︎
Weleber RG, et al. Clinical manifestations of the neuronal ceroid lipofuscinoses. 2018. ↩︎
Santorelli FM, et al. Epilepsy in neuronal ceroid lipofuscinoses: clinical features and treatment outcomes. 2019. ↩︎
Mink JW, et al. Motor decline in CLN2 disease: natural history and treatment outcomes. 2020. ↩︎
Adams D, et al. CLN2 disease: clinical rating scale development and validation. 2021. ↩︎
Schulz A, et al. Long-term efficacy of cerliponase alfa in CLN2 disease: 3-year open-label extension data. 2020. ↩︎
Pierpont EI, et al. Cognitive outcomes in CLN2 disease patients treated with cerliponase alfa. 2020. ↩︎
CLN2 Disease Registry. Real-world outcomes with cerliponase alfa: 5-year interim analysis. 2023. 2023. ↩︎
Parenti G, et al. New strategies for the treatment of lysosomal storage diseases. 2021. ↩︎
Biffi A. Gene therapy for metachromatic leukodystrophy. 2019. ↩︎
Giugliani R, et al. Intracerebroventricular enzyme replacement therapy for MPS I: preclinical and clinical considerations. 2018. ↩︎
Byrne BJ, et al. Pompe disease: to treat the heart and the brain. 2021. ↩︎
BioMarin Pharmaceutical. Brineura administration guide. 2022. 2022. ↩︎
Whitley CB, et al. Cerliponase alfa dosing and infusion protocols: consensus recommendations. 2019. ↩︎
Kwon JM, et al. Safety and tolerability of intracerebroventricular enzyme replacement therapy. 2020. ↩︎
Guffon N, et al. Intraventricular access device placement and management in enzyme replacement therapy. 2019. ↩︎
Stepien KM, et al. Pre-infusion assessment and monitoring protocols for cerliponase alfa. 2021. ↩︎
Lund AM, et al. Antihistamine and corticosteroid premedication for cerliponase alfa hypersensitivity. 2020. ↩︎
Thurner A, et al. Optimizing cerliponase alfa infusion parameters. 2021. ↩︎
Harmatz P, et al. Post-infusion monitoring in enzyme replacement therapy: best practice recommendations. 2020. ↩︎
Muenzer J, et al. Neurosurgical aspects of intraventricular access devices for enzyme replacement therapy. 2019. ↩︎
Scarborough P, et al. Device-related infection prevention in cerliponase alfa therapy. 2020. ↩︎
Jones SA, et al. Management of device complications in lysosomal enzyme replacement therapy. 2018. ↩︎
Wang D, et al. Meningitis in patients receiving intracerebroventricular enzyme therapy: recognition and management. 2021. ↩︎
Specchio N, et al. Seizure management in CLN2 disease: a position paper. 2021. ↩︎
Böhles H, et al. Anaphylactoid reactions to cerliponase alfa: a case series and review. 2019. ↩︎
Wang W, et al. Anti-drug antibody development in cerliponase alfa-treated patients: impact on efficacy and safety. 2020. ↩︎
Rane PB, et al. Peri-procedural antibiotic prophylaxis in enzyme replacement therapy. 2020. ↩︎
Giugliani R, et al. Corticosteroid premedication for immunomodulation in cerliponase alfa therapy. 2019. ↩︎
Hlavata I, et al. Cerebrospinal fluid TPP1 activity as a biomarker of treatment response. 2020. ↩︎
FDA News Release. FDA approves first treatment for a rare form of Batten disease. June 1, 2017. 2017. ↩︎
European Medicines Agency. Brineura assessment report. 2017. EMA/CHMP/295269/2017. 2017. ↩︎
Orphan Drug Designations and Approvals. Cerliponase alfa. Available at:. ↩︎